Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy - Concepedia

Concepedia

Publication | Closed Access

Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy

44

Citations

32

References

2021

Year

Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Yuki Tahata, Yasuharu Imai, Kazuyoshi Ohkawa, Masanori Miyazaki, Eiji Mita, Toshifumi Ito, Hideki Hagiwara,

Hepatology Research

Abstract

Hyperprogressive disease was observed in 10.2% of HCC patients receiving atezolizumab plus bevacizumab, and an elevated NLR at baseline had an increased risk of HPD.

References

	Year	Citations

Page 1